Methods for treating diabetes and reducing body weight

Abstract

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

1 - 133 . (canceled) 
     
     
         134 . A method for treating diabetes in a human in need thereof, the method comprising administering once monthly to the human an effective amount of a pharmaceutical composition comprising exendin-4 or an exendin analog to achieve a mean steady state plasma concentration of the exendin-4 or the exendin-4 analog at least 170 pg/ml for at least one month in the human to treat diabetes. 
     
     
         135 . The method of  claim 134 , wherein the pharmaceutical composition comprises exendin-4. 
     
     
         136 . The method of  claim 134 , wherein the pharmaceutical composition comprises the exendin analog. 
     
     
         137 . The method of  claim 136 , wherein the exendin analog comprises the amino acid sequence of any one of SEQ ID NOs: 2 and 9-142. 
     
     
         138 . The method of  claim 134 , wherein the pharmaceutical composition further comprises a sugar. 
     
     
         139 . The method of  claim 134 , wherein the pharmaceutical composition further comprises a poly(lactide-co-glycolide) copolymer. 
     
     
         140 . The method of  claim 139 , wherein the poly(lactide-co-glycolide) copolymer is purified 50:50 (lactide:glycolide) poly(D,L-lactide-co-glycolide). 
     
     
         141 . The method of  claim 134 , wherein the pharmaceutical composition comprises 5% (w/w) exendin-4, 2% (w/w) sucrose, and 93% (w/w) poly(lactide-co-glycolide)copolymer. 
     
     
         142 . The method of  claim 134 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 600 pg/ml. 
     
     
         143 . The method of  claim 134 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 350 pg/ml. 
     
     
         144 . The method of  claim 134 , wherein the mean steady state plasma concentration of exendin-4 or the exendin analog is 170 pg/ml to 290 pg/ml. 
     
     
         145 . The method of  claim 134 , wherein the diabetes is type 2 diabetes. 
     
     
         146 . The method of  claim 134 , wherein the diabetes is type I diabetes. 
     
     
         147 . A method for reducing HbA1C, fasting plasma glucose, or body weight in a human in need thereof, the method comprising administering once monthly to the human an effective amount of a pharmaceutical composition comprising exendin-4 or an exendin analog in an amount to achieve a mean steady state concentration of exendin-4 or the exendin analog of at least 170 pg/ml for at least one month to reduce HbA1C, fasting plasma glucose, or body weight. 
     
     
         148 . The method of  claim 147 , wherein the pharmaceutical composition comprises exendin-4. 
     
     
         149 . The method of  claim 147 , wherein the pharmaceutical composition further comprises a poly(lactide-co-glycolide) copolymer. 
     
     
         150 . The method of  claim 147 , wherein the method is for reducing HbA1C. 
     
     
         151 . The method of  claim 147 , wherein the method is for reducing fasting plasma glucose. 
     
     
         152 . The method of  claim 147 , wherein the method is for reducing body weight. 
     
     
         153 . A method for treating type 2 diabetes in a human in need thereof, the method comprising administering once monthly to the human an effective amount of a pharmaceutical composition comprising 5% (w/w) exendin-4, 2% (w/w) sucrose, and 93% (w/w) poly(lactide-co-glycolide)copolymer to achieve a mean steady state plasma concentration of exendin-4 at 170 pg/ml to 350 pg/ml for at least one month in the human to treat Type 2 diabetes.